Results:
Among the 147 patients who reached 24M of dulaglutide treatment in our
previous study,11 we selected a cohort of those had reached 36M with an
active prescription of dulaglutide. 52 of those were excluded because
they did not meet the inclusion criteria. Of the 95 initial patients, we
recorded eight drop-outs due to several causes (8.42%): (1) four due to
change of GLP-1 RA; (2) one death; (3) gastrointestinal side effects in
one and (4) two for unspecified causes.